
|Articles|September 1, 2003
Follow the Rules
Author(s)Alison Palkhivala
San Francisco - The known teratogenicity of isotretinoin, as well as a possible link to psychiatric illness, means that physicians prescribing the drug must carefully follow risk-management guidelines. These guidelines are mandated by the FDA.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















